Citations

Showing 10 of 108083 citations.

Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis.
Shmueli, Einat , Raeisi, Morteza , Hurwitz, Herbert I. , Kabbinavar, Fairooz F. , Sharara, Lama, Gramont, Aimery de , Chibaudel, Benoist , Saltz, Leonard B. , Tebbutt, Niall C. , Grothey, Axel , Adams, Richard , Zalcberg, John , Yoshino, Takayuki , Bachet, Jean‐Baptiste , Cohen, Romain , André, Thierry , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 118-118

10.1200/jco.2023.41.4_suppl.118 Get It

118 Background: Anti-VEGF is widely used in the treatment (trt) of metastatic colorectal cancer (mCRC). Only studies with bevacizumab (BEV) have shown survival benefit (bnf) in first line trt. The magnitude of bnf might differ based on the metastatic (met) site and the chemotherapy regimen (CTR) with which BEV is partnered. ARCAD database contains individual patient data (IPD) of randomized trials that evaluated BEV+ CT. In this pooled analysis, we aimed to evaluate BEV bnf in mCRC with lung metastases (mets) either as single or multiple sites. Methods: IPD from four trials (AVF2107g, N016966, AVF2192g, AGITG) comparing CT +/- BEV were pooled. The primary endpoint, overall survival (OS), was estimated using Kaplan-Meier method and prognostic value of lung mets was evaluated by stratified Cox models according to number and type of met sites and CTRs, oxaliplatin or irinotecan (OX/IRI) based. The predictive bnf of BEV was evaluated by interaction test (int) between trt and lung mets status in subgroups and considered as significant (sig) with a P < 0.1. Results: 2728 patients (pts) with known met sites and survival data were pooled. 1020 pts had single met site, 133 had only lung mets. 1708 pts had multiple met sites, 1008 had lung mets. Pts characteristics were well balanced. Sig OS bnf of BEV was observed in the whole population. In pts subgroup according to the presence or absence of lung mets, sig bnf of BEV were observed with a non-sig int ( Pint=.590). Non-sig bnf of BEV was observed in pts with single site regardless of met site (lung or no lung) or CTR. Sig bnf of BEV was observed in pts with multiple sites without lung mets whatever the CTRs. While sig bnf of BEV was observed in pts with multiple sites with lung mets, we found a sig int between BEV and OX/IRI-based regimens ( Pint=.022). The bnf of BEV was observed with IRI-based regimen but not in OX-based regimen. The bnf of BEV appears greater in multiple sites without lung mets than with lung mets with a sig stratified log-rank test ( PLRT<.001). Conclusions: In pts with multiple sites mCRC, a statistically sig OS bnf of BEV added to CT was observed mainly among pts without lung mets. The overall effect of CT partner choice when combined with BEV can be different. In pts with single site, BEV did not seem to improve OS but the evaluation of efficacy of BEV in presence or absence lung mets was based on small number of pts and needs to be evaluated in trials with larger pts sample, especially trials including pts with single site lung mets. [Table: see text]
The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability–high (dMMR/MSI-H) localized and oligometastatic colon cancer: Data from the real world.
Parish, Marie, Peterson, Carrie Y. , Sriram, Deepika, Ruggeri, Antony, Tolay, Sameer, Bajor, David L. , Mohamed, Amr , Shreenivas, Aditya , Chakrabarti, Sakti , LUDWIG, KIRK A. , Selfridge, Jennifer Eva , Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 105-105

10.1200/jco.2023.41.4_suppl.105 Get It

105 Background: Patients with potentially resectable dMMR/MSI-H colon cancer (CC) often receive neoadjuvant immunotherapy (IO) if co-morbid conditions or the extent of disease preclude upfront surgery. We investigated the outcome of such patients treated in a real-world setting. Methods: This is a single-center retrospective study that included patients with dMMR/MSI-H localized and oligometastatic CC receiving neoadjuvant IO between January 1, 2016, and July 31, 2022 with a data cut-off date of September 15, 2022. Electronic charts were reviewed to gather data on patient characteristics, tumor characteristics, detailed treatment, toxicity, treatment response, and survival. The response was assessed by radiologic studies, endoscopy, pathology in resected patients, and circulating tumor DNA. Results: The study included 24 patients with a median age of 69 years (range, 32 to 91); 12 (50%) patients were female, and 5 (21%) patients were African American. Among the patients included, 12 (50%) had localized CC (9 of whom had clinical stage III disease), and the rest had oligometastatic CC. The reasons for not undergoing upfront surgery were co-morbidity in 12 patients (50%), disease extent in 11 (46%), and both in 1 (4%). Four patients (17%) received the ipilimumab/nivolumab combination, and the rest received pembrolizumab. Most patients (63%) received IO in the first-line setting. The median duration of IO and the time to best response were 7.5 months (range, 2 to 55) and 3 months (range, 3 to 12), respectively. Among 23 evaluable patients, the overall response rate (ORR) was 74 % (17/23), with complete response (CR) in 13 (57%), and partial response (PR) in 4 (17%) patients. Response assessment is pending in 1 patient. Four patients (17%) had stable disease (SD), and 2 patients (8 %) experienced progressive disease (PD) on IO (1 with localized and the other with metastatic CC). The median progression-free survival (PFS) and overall survival (OS) did not reach for the whole group after a median follow-up of 12.5 months (range, 2 to 69 months), with 19/24 (79 %) patients remaining progression-free. Three patients underwent surgery with 2/3 achieving pathological CR. Among the 12 patients with localized CC, ORR was 73% (6 CR, 2 PR, 2 SD, 1 PD, and 1 assessment pending); median PFS and OS were not reached after a median follow-up of 9 months (range, 2 to 45) with 1 patient experiencing progression on IO at the time of data cut-off. No unexpected toxicity was observed. Conclusions: In this small cohort of patients with dMMR/MSI-H localized and oligometastatic CC, most patients showed deep and durable responses to neoadjuvant IO, obviating the need for surgery. Progression on IO was rare. This real-world data support investigating a non-operative paradigm in patients with dMMR/MSI-H localized and oligometastatic CC.
Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study
Aby, Elizabeth S. , Moafa, Ghady, Sultan, Mohammad T., Cacioppo, Paula A., Kumar, Sonal , Chung, Raymond , Bloom, Patricia P. , Gustafson, Jenna , Daidone, Michael , Reinus, Zoe, Debes, José D. , Sandhu, Sunny , Khalid, Sameeha , Roytman, Marina , Catana, Andreea M. , Wegermann, Kara , Carr, Rotonya M. , Saiman, Yedidya , Kassab, Ihab , Chen, Vincent , Rabiee, Atoosa , Rosenberg, C. E., Nguyen, Veronica , Gainey, Christina S. , Chavin, Kenneth D. , Chascsa, David M. , Varelas, Lee , Moghe, Akshata , Dhanasekaran, Renumathy , Latt, Nyan , Bloom, Patricia P , Debes, Jose D , Sandhu, Sunny , Sohal, Aalam , Khalid, Sameeha , Roytman, Marina , Catana, Andreea Maria , Wegermann, Kara , Carr, Rotonya M , Chen, V L , Rabiee, Atoosa , Nguyen, Veronica , Gainey, Christina , Zhou, Kali , Chavin, Kenneth , Lizaola-Mayo, Blanca , Chascsa, David M , Varelas, Lee , Dhanasekaran, Renumathy , Lizaola‐Mayo, Blanca

Mayo Clinic

Hepatology Communications | January 24, 2023 | Volume: 7 | Issue: 1 | Pages: e8874-e8874

10.1097/01.hc9.0000897224.68874.de | PMID 36633476 Get It

Background: COVID-19 is associated with higher morbidity and mortality in patients with chronic liver diseases (CLDs). However, our understanding of the long-term outcomes of COVID-19 in patients with CLD is limited. Methods: We conducted a multicenter, observational cohort study of adult patients with CLD who were diagnosed with COVID-19 before May 30, 2020, to determine long-term clinical outcomes. We used a control group of patients with CLD confirmed negative for COVID-19. Results: We followed 666 patients with CLD (median age 58 years, 52.8% male) for a median of 384 (interquartile range: 31–462) days. The long-term mortality was 8.1%; with 3.6% experiencing delayed COVID-19-related mortality. Compared to a propensity-matched control group of patients with CLD without COVID-19 (n=1332), patients with CLD with COVID-19 had worse long-term survival [p<0.001; hazards ratio (HR): 1.69; 95% CI: 1.19–2.41] and higher rate of hospitalization (p<0.001, HR: 2.00, 1.62–2.48) over a 1-year follow-up period. Overall, 29.9% of patients reported symptoms of long-COVID-19. On multivariable analysis, female sex (p=0.05, HR: 2.45, 1.01–2.11), Hispanic ethnicity (p=0.003, HR: 1.94, 1.26–2.99), and severe COVID-19 requiring mechanical ventilation (p=0.028, HR: 1.74, 1.06–2.86) predicted long-COVID-19. In survivors, liver-related laboratory parameters showed significant improvement after COVID-19 resolution. COVID-19 vaccine status was available for 72% (n=470) of patients with CLD and history of COVID-19, of whom, 70% (n=326) had received the COVID-19 vaccine. Conclusions: Our large, longitudinal, multicenter study demonstrates a high burden of long-term mortality and morbidity in patients with CLD and COVID-19. Symptoms consistent with long-COVID-19 were present in 30% of patients with CLD. These results illustrate the prolonged implications of COVID-19 both for recovering patients and for health care systems.
Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies
Curry, Michael P. , Vargas, Hugo E. , Befeler, Alex S. , Pyrsopoulos, Nikolaos , Patwardhan, Vilas , Jamil, Khurram , Pyrsopoulos, Nikolaos T , Patwardhan, Vilas R , Vargas, Hugo E , Jamil, Khurram

Mayo Clinic

Hepatology Communications | January 24, 2023 | Volume: 7 | Issue: 1 | Pages: e1307-e1307

10.1097/01.hc9.0000897228.91307.0c | PMID 36633470 Get It

Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function. Liver transplantation remains the only curative treatment for decompensated cirrhosis. However, terlipressin, a vasopressin analog, successfully reverses HRS-1, and may improve patient survival while awaiting liver transplantation. Patients with higher baseline serum creatinine have a reduced response to treatment with terlipressin. These post hoc analyses examined pooled data from 352 patients with HRS-1 treated with terlipressin in 3 North American-centric, Phase III, placebo-controlled clinical studies (i.e. OT-0401, REVERSE, and CONFIRM)—across 3 serum creatinine subgroups (i.e. <3, ≥3–<5, and ≥5 mg/dL)—to further delineate their correlation with HRS reversal, renal replacement therapy-free survival, and overall survival. Serum creatinine was significantly associated with HRS reversal in univariate and multivariate logistic regression analyses (P<0.001). The incidence of HRS reversal inversely correlated with serum creatinine subgroup (<3 mg/dL, 49.2%; ≥3–<5 mg/dL, 28.0%; ≥5 mg/dL, 9.1%). At Day 30 follow-up, renal replacement therapy-free survival was significantly higher for patients with HRS-1 in the lower serum creatinine subgroups than in the higher subgroup (<5 vs. >5 mg/dL; p=0.01). Terlipressin-treated patients with HRS-1, with a lower baseline serum creatinine level, had a higher overall survival (p<0.001) and higher transplant-free survival at Day 90 (p=0.04). Patients with HRS-1 and lower serum creatinine levels who were treated with terlipressin had higher HRS reversal and survival outcomes, highlighting the significant need to identify and treat patients with HRS-1 early when they often have lower serum creatinine levels, and likely a greater response to terlipressin.
Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.
Haimi, Ido, Dettwyler, Shenin A. , Bi, Yan , Chung, Daniel C. , Farrell, James J. , Kastrinos, Fay , Klute, Kelsey , Sussman, Daniel A. , Zogopoulos, George , Everett, Jessica N. , Brand, Randall E. , Grossberg, Aaron J. , Katona, Bryson W , Kupfer, Sonia S. , Lucas, Aimee Lee , Paiella, Salvatore , Parmigiani, Giovanni , Permuth, Jennifer B. , Sears, Rosalie C. , Simeone, Diane M.

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 689-689

10.1200/jco.2023.41.4_suppl.689 Get It

689 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer typically discovered at incurable stages. The PRECEDE Consortium was established to accelerate early detection by using a large-scale, collaborative, innovative model, predicated on standardized collection of demographic, clinical, and imaging data from high-risk individuals (HRI). Here we report the initial pancreas imaging findings in Cohort 1, representing HRI with familial pancreatic cancer (FPC) or pathogenic germline variants (PGV) in PDAC susceptibility genes with a 1 st or 2 nd degree relative with PDAC. Methods: The PRECEDE Consortium (NCT04970056) began enrollment in 5/2020. HRI enrolled prospectively at centers worldwide into one of 7 cohorts based on personal and/or family history of PDAC and PGV status. PRECEDE’s planned enrollment is 10,000 patients. Data sharing is required to join PRECEDE, facilitated by a standardized data collection system and central database (PRECEDELink). Imaging (MRI/MRCP and EUS) is performed using standardized image acquisition and reporting templates. Imaging and clinical sequencing data are stored and analyzed in the PRECEDE data cloud. Results: By 9/16/2022, 26 sites enrolled 3156 patients in 7 cohorts, with 1716 in Cohort 1. Cohort 1 was 60% female, 80% white; 48% met FPC criteria, and 52% were PGV carriers. Within Cohort 1, 658 FPC and 965 PGV (1353 total, 79%) underwent imaging (68% MRI; 32% EUS). Overall, 573/1353 (42%) had pancreas abnormalities: 320/573 (49%) FPC, and 253/573 (36%) PGV (OR [95% CI] 1.65 [1.32–2.06], P < 0.001). Cysts were the most common abnormality, present in 549/1353 (41%) and accounting for 310/320 (97%) FPC and 239/253 (94%) PGV HRI abnormalities. Of 549 HRI with cysts, 262 (48%) had 1 cyst, including 137/310 (44%) FPC and 125/239 (52%) PGV HRI (OR 1.43 [1.07–1.92], P = .012) The remaining 287/549 (52%) had ≥2 cysts, including 173/310 (56%) FPC and 114/239 (48%) PGV HRI (OR 1.98 [1.49–2.64], P < 0.001). Worrisome features occurred in 83/1353 (6.1%) including: 14 (1%) cyst > 2 cm, 7 (0.5%) cyst ≥3 cm, 35 (2.6%) main pancreatic duct (MPD) diameter ≥5 mm; 2 (0.15%) duct strictures; and 25 (1.8%) solid masses. Solid masses included 1 (0.07%) PDAC, 9 (0.7%) neuroendocrine tumors, and 15 (1.1%) benign lesions (e.g. lipoma, splenule). Conclusions: Pancreatic abnormalities are common in a cohort of 1353 HRI enrolled in PRECEDE; 6.1% of HRI had findings with worrisome features and clinical implications. Multiple cysts were significantly more common in FPC HRI (OR 1.98); worrisome findings did not differ between FPC and PGV groups. The longitudinal study of this growing HRI cohort with standardized imaging and matched comprehensive epidemiological, clinical, and laboratory data, along with germline testing, will provide critical information and understanding of PDAC risk, and augment existing clinical decision-making models governing surveillance and treatment.
Response to letter to the editor on: Interpreting the effectiveness of cognitive behavioural therapy (CBT) and self-management strategies in heart failure patients for improving sleep’, in response to the article—‘coping, symptoms, and insomnia among peopl
Redeker, Nancy S. , O’Connell, Meghan , Conley, Samantha , Conley, Samantha , Redeker, Nancy S

Mayo Clinic

European Journal of Cardiovascular Nursing | January 24, 2023 | Volume: 22 | Issue: 3 | Pages: e27-e28

10.1093/eurjcn/zvad016 | PMID 36692219 Get It

The status of digital pathology and associated infrastructure within Alzheimer’s Disease Centers
Scalco, Rebeca , Hamsafar, Yamah, Reichard, R. Ross , Perrin, Richard J. , Nelson, Peter T. , Lieberman, Andrew P. , Kukull, Walter A. , Kofler, Julia , Gutman, David A. , Crary, John F. , Chan, Kwun C, Dugger, Brittany N. , Reichard, Robert Ross, Dugger, Brittany N , White, Charles L. , Schneider, Julie A. , Prokop, Stefan , Mooney, Sean D. , Keene, C. Dirk , Kapasi, Alifiya , Irwin, David J. , Flanagan, Margaret E. , Murray, Melissa E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | January 24, 2023 | Volume: 82 | Issue: 3 | Pages: 202-211

10.1093/jnen/nlac127 | PMID 36692179 Get It

Abstract Digital pathology (DP) has transformative potential, especially for Alzheimer disease and related disorders. However, infrastructure barriers may limit adoption. To provide benchmarks and insights into implementation barriers, a survey was conducted in 2019 within National Institutes of Health’s Alzheimer’s Disease Centers (ADCs). Questions covered infrastructure, funding sources, and data management related to digital pathology. Of the 35 ADCs to which the survey was sent, 33 responded. Most respondents (81%) stated that their ADC had digital slide scanner access, with the most frequent brand being Aperio/Leica (62.9%). Approximately a third of respondents stated there were fees to utilize the scanner. For DP and machine learning (ML) resources, 41% of respondents stated none was supported by their ADC. For scanner purchasing and operations, 50% of respondents stated they received institutional support. Some were unsure of the file size of scanned digital images (37%) and total amount of storage space files occupied (50%). Most (76%) were aware of other departments at their institution working with ML; a similar (76%) percentage were unaware of multiuniversity or industry partnerships. These results demonstrate many ADCs have access to a digital slide scanner; additional investigations are needed to further understand hurdles to implement DP and ML workflows.
Emergence of restless legs syndrome during opioid discontinuation
McCarter, Stuart J. , Labott, Joshua R. , Mazumder, Mridul , Gebhard, Judy, Cunningham, Julie L. , Loukianova, Larissa L., Gilliam, Wesley P. , Lipford, Melissa C. , McCarter, Stuart J

Mayo Clinic

Journal of Clinical Sleep Medicine | January 24, 2023 | Volume: 19 | Issue: 4 | Pages: 741-748

10.5664/jcsm.10436 | PMID 36692170 Get It

Examining the feasibility of adult quality-of-life measurement for obstructive sleep apnea in clinical settings: what is the path forward for sleep centers?
Colvin, Loretta , Collop, Nancy A. , Lorenz, Rebecca , Weaver, Terri E. , Morgenthaler, Timothy, Morgenthaler, Timothy I.

Mayo Clinic

Journal of Clinical Sleep Medicine | January 24, 2023 | Volume: 19 | Issue: 6 | Pages: 1145-1155

10.5664/jcsm.10438 | PMID 36692175 Get It

Non–race-based Glomerular Filtration Rates to Estimate Renal Functional Outcomes Following Radical and Partial Nephrectomy
Britton, Cameron J. , Sharma, Vidit , Lohse, Christine M. , Thompson, R. Houston, Potretzke, Aaron M. , Lieske, John C. , Rule, Andrew D.

Mayo Clinic

Urology Practice | January 24, 2023 | Volume: 10 | Issue: 3 | Pages: 213-216

10.1097/upj.0000000000000389 | PMID 37103500 Get It